
A Stanford bioengineer became a venture investor with an unusually broad portfolio. Then he left the partnership to help build the kind of ambitious company he had spent a decade backing.
At UCSF, Jacob Kimmel studied what a cell’s movement could reveal. At NewLimit, the co-founder and CEO is working at a far larger scale, but the old question still follows him: what can a good measurement make possible?